Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer

被引：5
|
作者：
Boccardo, F. [1 ,2 ]
机构：
[1] Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy
[2] Natl Inst Canc Res, Acad Unit Med Oncol, Genoa, Italy
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 02期
关键词：
D O I：
10.1038/ncponc1015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76 / 77
页数：2
相关论文
共 50 条
  • [31] Thyroid function in postmenopausal women with breast cancer on tamoxifen
    Kostoglou-Athanassiou, I
    Ntalles, K
    Markopoulos, C
    Athanassiou, P
    Gogas, J
    Proukakis, C
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 1998, 19 (02) : 150 - 154
  • [32] ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial-anastrozole is superior to tamoxifen as adjuvant treatment in postmenopausal women with early breast cancer.
    Bianco, R
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S155 - S155
  • [33] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
    Simons, WR
    Jones, D
    Buzdar, A
    CLINICAL THERAPEUTICS, 2003, 25 (11) : 2972 - 2987
  • [34] The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer - a randomised study.
    Kataja, V
    Hietanen, P
    Joensuu, H
    Ala-Luhtala, T
    Asola, R
    Kokko, R
    Holli, K
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S156 - S156
  • [35] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
    Boccardo, F.
    Rubagotti, A.
    Guglielmini, P.
    Fini, A.
    Paladini, G.
    Mesiti, M.
    Rinaldini, M.
    Scali, S.
    Porpiglia, M.
    Benedetto, C.
    Restuccia, N.
    Buzzi, F.
    Franchi, R.
    Massidda, B.
    Distante, V.
    Amadori, D.
    Sismondi, P.
    ANNALS OF ONCOLOGY, 2006, 17 : VII10 - VII14
  • [36] Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole
    Van Calster, Ben
    Van Ginderachter, Johan
    Vlasselaer, Jos
    Van de Putte, Gregg
    Berteloot, Patrick
    Timmerman, Dirk
    Depypere, Herman
    Blomme, Chantal
    Vlaemynck, Geert
    De Jonge, Eric
    Van den Broecke, Rudy
    Vergote, Ignace
    Amant, Frederic
    Van Huffel, Sabine
    Neven, Patrick
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2011, 18 (02): : 224 - 229
  • [37] Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole
    Ingle, James N.
    Kalari, Krishna R.
    Buzdar, Aman U.
    Robson, Mark E.
    Goetz, Matthew P.
    Desta, Zeruesenay
    Barman, Poulami
    Dudenkov, Tanda T.
    Northfelt, Donald W.
    Perez, Edith A.
    Flockhart, David A.
    Williard, Clark V.
    Wang, Liewei
    Weinshilboum, Richard M.
    STEROIDS, 2015, 99 : 32 - 38
  • [38] Breast cancer prevention using anastrozole in postmenopausal women at high risk
    Cuzick, J.
    Sestak, I.
    Forbes, J. F.
    Dowsett, M.
    Knox, J.
    Cawthorn, S.
    Saunders, C.
    Roche, N.
    Mansel, R. E.
    von Minckwitz, G.
    Bonanni, B.
    Palva, T.
    Howell, A.
    CANCER RESEARCH, 2013, 73
  • [39] Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer
    Kyvernitakis, I.
    Albert, U-S.
    Kalder, M.
    Winarno, A-S.
    Hars, O.
    Hadji, P.
    CLIMACTERIC, 2015, 18 (01) : 63 - 68
  • [40] Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women
    Jahanzeb, Mohammad
    CLINICAL THERAPEUTICS, 2007, 29 (08) : 1535 - 1547
12345